Literature DB >> 2360819

Theophylline dosage adjustment during enoxacin coadministration.

J R Koup1, R D Toothaker, E Posvar, A J Sedman, W A Colburn.   

Abstract

Based on the results of a previous study which demonstrated a 50% reduction in theophylline clearance during coadministration of 400 mg of enoxacin twice a day (b.i.d.), a sequential-design study was completed with seven nonsmoking, healthy adult female human volunteers. The subjects were given 200 mg of theophylline (Theo-Dur) orally every 12 h for 4 days. On day 5, the subjects began receiving 400 mg of enoxacin with each theophylline dose, and the dosage of theophylline was reduced to 100 mg b.i.d. This regimen was continued through day 8, after which enoxacin was discontinued. The theophylline dosage was increased to 200 mg b.i.d. on day 9, and theophylline monotherapy continued through day 12. The mean apparent theophylline clearance decreased by approximately 50% during enoxacin coadministration. No significant differences in mean theophylline maximum concentration in serum, time to maximum concentration in serum, lowest concentration observed, or area under the concentration-time curve during the steady-state dosing were observed before, during, or after enoxacin coadministration when the theophylline dosage was reduced to 100 mg b.i.d. Reduction of the theophylline dose by 50% at the onset of enoxacin dosing maintained constant theophylline concentrations in plasma. A return to the original theophylline dose immediately upon cessation of enoxacin therapy resulted in a transient 35% increase in theophylline concentrations in plasma which lasted 24 to 48 h before returning to preenoxacin values. Although a 50% reduction in the theophylline dose maintained constant mean theophylline concentrations when enoxacin was administered concomitantly, it appears that larger dose reductions (up to 75%) could be required in patients with high theophylline clearances. In addition, larger transient increases in the theophylline concentration in plasma may be observed in these patients upon cessation of enoxacin therapy if the theophylline dose is immediately returned to normal. Thus, it is recommended that theophylline concentrations in plasma be monitored when concurrent enoxacin therapy is required.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360819      PMCID: PMC171695          DOI: 10.1128/AAC.34.5.803

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.

Authors:  M C Rogge; W R Solomon; A J Sedman; P G Welling; J R Koup; J G Wagner
Journal:  Clin Pharmacol Ther       Date:  1989-10       Impact factor: 6.875

2.  Microassay for the simultaneous determination of theophylline and dyphylline in serum by high-performance liquid chromatography.

Authors:  M B Kester; C L Saccar; H C Mansmann
Journal:  J Chromatogr       Date:  1987-04-24

3.  Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics.

Authors:  P H Scott; E Tabachnik; S MacLeod; J Correia; C Newth; H Levison
Journal:  J Pediatr       Date:  1981-09       Impact factor: 4.406

4.  The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition.

Authors:  M C Rogge; W R Solomon; A J Sedman; P G Welling; R D Toothaker; J G Wagner
Journal:  Clin Pharmacol Ther       Date:  1988-11       Impact factor: 6.875

5.  The influence of quinolone derivatives on theophylline clearance.

Authors:  W J Wijnands; T B Vree; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

6.  Enoxacin--a potent inhibitor of theophylline metabolism.

Authors:  J Beckmann; W Elsässer; U Gundert-Remy; R Hertrampf
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  6 in total
  5 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin.

Authors:  N M Waite; M J Rybak; D J Krakovsky; J D Steinberg; L H Warbasse; D J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

Review 3.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

4.  Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Authors:  G H Talbot; P A Cassileth; L Paradiso; R Correa-Coronas; L Bond
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 5.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.